Johnson & Johnson Past Earnings Performance
Past criteria checks 4/6
Johnson & Johnson's earnings have been declining at an average annual rate of -1.7%, while the Pharmaceuticals industry saw earnings declining at 2.4% annually. Revenues have been growing at an average rate of 0.7% per year. Johnson & Johnson's return on equity is 22.9%, and it has net margins of 18.9%.
Key information
-1.7%
Earnings growth rate
-0.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 0.7% |
| Return on equity | 22.9% |
| Net Margin | 18.9% |
| Next Earnings Update | 15 Oct 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Johnson & Johnson makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 86,576 | 16,382 | 21,050 | 14,909 |
| 31 Mar 24 | 85,648 | 17,072 | 20,640 | 15,172 |
| 31 Dec 23 | 85,159 | 13,326 | 20,166 | 15,085 |
| 01 Oct 23 | 83,703 | 12,421 | 19,738 | 14,315 |
| 02 Jul 23 | 82,348 | 12,422 | 19,323 | 14,353 |
| 02 Apr 23 | 77,458 | 10,730 | 17,993 | 14,128 |
| 01 Jan 23 | 79,990 | 16,370 | 19,078 | 14,135 |
| 02 Oct 22 | 84,855 | 17,879 | 21,037 | 15,145 |
| 03 Jul 22 | 88,197 | 17,236 | 22,197 | 15,082 |
| 03 Apr 22 | 94,880 | 19,830 | 24,430 | 14,998 |
| 02 Jan 22 | 78,740 | 17,801 | 19,506 | 14,277 |
| 03 Oct 21 | 91,446 | 17,880 | 23,364 | 14,026 |
| 04 Jul 21 | 89,190 | 17,767 | 22,852 | 13,444 |
| 04 Apr 21 | 84,214 | 15,115 | 21,817 | 12,757 |
| 03 Jan 21 | 82,584 | 14,714 | 21,731 | 12,159 |
| 27 Sep 20 | 80,856 | 16,986 | 21,681 | 11,359 |
| 28 Jun 20 | 80,503 | 15,185 | 21,625 | 11,118 |
| 29 Mar 20 | 82,729 | 17,166 | 22,185 | 11,077 |
| 29 Dec 19 | 82,059 | 15,119 | 21,885 | 11,355 |
| 29 Sep 19 | 81,706 | 14,151 | 21,957 | 11,347 |
| 30 Jun 19 | 81,325 | 16,332 | 22,191 | 11,256 |
| 31 Mar 19 | 81,593 | 14,679 | 22,437 | 11,229 |
| 30 Dec 18 | 81,581 | 15,297 | 22,540 | 10,775 |
| 30 Sep 18 | 81,382 | 1,542 | 22,454 | 11,194 |
| 01 Jul 18 | 80,684 | 1,372 | 22,300 | 11,271 |
| 01 Apr 18 | 78,693 | 1,245 | 21,758 | 10,928 |
| 31 Dec 17 | 76,450 | 1,300 | 21,520 | 10,594 |
| 01 Oct 17 | 74,361 | 15,827 | 20,600 | 9,591 |
| 02 Jul 17 | 72,531 | 16,335 | 20,012 | 9,184 |
| 02 Apr 17 | 72,174 | 16,505 | 20,020 | 9,152 |
| 01 Jan 17 | 71,890 | 16,540 | 19,793 | 9,143 |
| 02 Oct 16 | 71,595 | 15,941 | 20,527 | 9,319 |
| 03 Jul 16 | 70,877 | 15,027 | 20,836 | 9,295 |
| 03 Apr 16 | 70,182 | 15,546 | 21,044 | 9,160 |
| 03 Jan 16 | 70,074 | 15,409 | 21,203 | 9,046 |
| 27 Sep 15 | 70,517 | 14,715 | 21,134 | 8,817 |
| 28 Jun 15 | 71,882 | 16,106 | 21,521 | 8,686 |
| 29 Mar 15 | 73,590 | 15,916 | 21,618 | 8,562 |
| 28 Dec 14 | 74,331 | 16,323 | 21,954 | 8,494 |
| 28 Sep 14 | 74,232 | 17,321 | 22,049 | 8,270 |
| 29 Jun 14 | 73,340 | 15,554 | 21,895 | 8,289 |
| 30 Mar 14 | 71,722 | 15,061 | 21,790 | 8,230 |
| 29 Dec 13 | 71,312 | 13,831 | 21,830 | 8,183 |
| 29 Sep 13 | 70,515 | 12,879 | 21,574 | 8,103 |
Quality Earnings: 0R34 has a large one-off loss of $7.0B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 0R34's current net profit margins (18.9%) are higher than last year (15.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0R34's earnings have declined by 1.7% per year over the past 5 years.
Accelerating Growth: 0R34's earnings growth over the past year (32.3%) exceeds its 5-year average (-1.7% per year).
Earnings vs Industry: 0R34 earnings growth over the past year (32.3%) exceeded the Pharmaceuticals industry 4.5%.
Return on Equity
High ROE: 0R34's Return on Equity (22.9%) is considered high.